Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 47Glioblastoma 47Breast Neoplasms 40Esophageal Neoplasms 36Rectal Neoplasms 35Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 33Head and Neck Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Brain Neoplasms 23Pancreatic Neoplasms 22Neoplasms 19Uterine Cervical Neoplasms 17Oropharyngeal Neoplasms 16Neoplasm Metastasis 16Gliosarcoma 16Esophageal Squamous Cell Carcinoma 16Glioma 15Sarcoma 14Melanoma 14Stomach Neoplasms 12Adenocarcinoma Of Esophagus 12Lymphoma, Follicular 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Anus Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Endometrial Neoplasms 7

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Resectable Esophageal Cancer × Radiation × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡